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Summary 
Diabetes mellitus is characterized by oxidative stress, which in 
turn determines endothelial dysfunction. Gliclazide is a 
sulphonylurea antidiabetic drug with antioxidant effects due to its 
azabicyclo-octyl ring. It has been reported to potentially protect 
the vasculature through improvements in plasma lipid levels and 
platelet function. We hypothesized that gliclazide has a beneficial 
effect on endothelial function in Goto-Kakizaki rats (GK), an 
animal model of type 2 diabetes fed an atherogenic diet for 4 
months. We evaluated the influence of gliclazide on both 
metabolic and oxidative status and NO-mediated vasodilation. 
GKAD rats showed increased oxidative stress and impaired 
endothelium-dependent vasodilation. GKAD rats treated with 
gliclazide showed increased sensitivity to NO-mediated 
vasodilation, a significant decrease in fasting glycemia and 
insulinemia, and a significant decrease in systemic oxidative 
stress. In conclusion, our results suggest that gliclazide treatment 
improves NO-mediated vasodilation in diabetic GK rats with 
dyslipidemia probably due to its antioxidant effects, although we 
cannot rule out substantial benefits due to a reduction in fasting 
blood glucose. The availability of a compound that 
simultaneously decreases hyperglycemia, hyperinsulinemia, and 
inhibits oxidative stress is a promising therapeutic candidate for 
the prevention of vascular complications of diabetes. 
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Introduction 
 
The increase in oxidative stress that is associated 
with the chronic hyperglycemia of diabetes mellitus plays 
a key role in the genesis of endothelial dysfunction 
(Giugliano et al. 1996, Pennathur and Heinecke 2004). 
Agents with antioxidant properties improve the function 
of the vessels in animal models of diabetes (Da Ros et al. 
2004, Hamilton et al. 2007). We have recently reported 
that impaired endothelial dysfunction and increased 
oxidative stress was improved by α-lipoic acid, in old 
Goto-Kakizaki diabetic rats (Sena et al. 2008).  
Gliclazide is a second-generation sulfonylurea 
antihyperglycemic agent (Campbell et al. 1991) that 
stimulates insulin secretion from pancreatic β cells by 
inhibiting ATP-dependent potassium channels. ATP-
dependent potassium channels also mediate a variety of 
functions in heart and blood vessels (Nichols and Lederer 
1992) Thus it is possible that sulfonylurea agents would 
have some effects on the vascular function aside from 
their effects on glycemic control. In diabetic animal 
models, it has also been reported that gliclazide 
potentially protects the vasculature through 
improvements in plasma lipids and platelet function 
(Palmer and Brogden 1993). Mechanisms may include 
the ability of the drug to increase tissue plasminogen 
activator, and its properties as a free radical scavenger. 
(Scott et al. 1991, Jennings et al. 1992, Desfaits et al. 
1997, O'Brien et al. 2000). The aim of the present work 
was to address whether the gliclazide influenced 
endothelial dysfunction and oxidative stress in Goto-
Kakizaki diabetic rats fed a high-fat diet.  
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Methods 
 
Experimental animals 
Wistar and Goto-Kakizaki rats were obtained 
from our local breeding colony (Animal Research Center 
Laboratory, University Hospital, Coimbra, Portugal). 
Animals were subjected to a constant daily cycle of 12 h 
light and 12 h darkness and constant temperature  
(22-24 ºC) and humidity (50-60 %), with free access to 
water and to normal or high-fat diet between 2 and 6 
months of age [Special diet 0125 (Modified A04 from 
Charles River), SAFE, France].  
Rats were divided in four experimental groups 
accordingly [Wistar non-diabetic rats (W, n=12), GK 
diabetic rats fed a normal diet (GK control, n=16), GK 
diabetic rats fed an AD diet (GKAD, n=15), and GK rats 
fed an AD diet and treated with gliclazide (GKAD+G, 
n=14)]. Gliclazide (10 mg/kg/day) was administered in 
drinking water during four weeks before sacrifice. The 
experimental protocol was approved by the local 
Institutional Animal Care and Use Committee. 
 
Determination of metabolic and oxidative stress 
parameters  
After a 15-h fast, animals were anesthetized with 
ketamine/chlorpromazine. Blood was taken by heart 
puncture for determination of lipids, lipid peroxides, free 
fatty acid levels and insulin. For glucose tolerance tests, 
rats were fasted overnight and were given an 
intraperitoneal injection of glucose (1.75 g kg-1 body 
weight) in phosphate buffered saline (PBS). Blood 
glucose was determined by sampling from the tail vein at 
0, 30, 60, 90 and 120 min after injection by a glucose-
oxidase method using a glucometer (Glucometer-Elite-
Bayer, Portugal S.A.) and compatible reactive test strips. 
Fasting plasma lipids (total and HDL cholesterol, 
triglycerides and phospholipids) and plasma insulin levels 
were quantified using commercially available kits and by 
an in-house enzyme-linked immunosorbent assay (Seiça 
et al. 2004, Sena et al. 2007), respectively. Plasma free 
fatty acids (FFA) levels were evaluated using enzymatic 
assay kits (Roche Applied Science, Portugal). Rats were 
placed in metabolic cages for 24 h and urine collected. 
Urinary 8-hydroxydeoxyguanosine (8-OHdG), and 
plasma carbonyl protein concentration were measured 
using ELISA kits (OXIS health Products, Portland, OR, 
USA, Cayman Chemical Company, USA). 
 
Isometric tension studies 
Aorta were rapidly excised and freed of 
connective tissue. The aorta was divided into two segments 
(4 mm width). Ring segments were mounted between 
stainless steel triangles into individual organ chambers 
filled with oxygenated (95 % O2, 5 % CO2) Krebs-
Henseleit buffer (37 °C, pH 7.4) (composition in mmol l-1: 
NaCl 119; KCl 4.7; CaCl2 1.6; MgSO4 1.2; NaHCO3 25; 
KH2PO4 1.2; glucose 11.0). Indomethacin in a 
concentration of 10 µmol l-1 was present in all the 
experiments to inhibit prostaglandin synthesis. Aortic rings 
were subjected to a resting tension of 1.5 g. After 
equilibration for 60 min all vessels were preconstricted 
with 0.3 µM phenylephrine. Ligand-stimulated receptor-
mediated NO bioavailability was assessed by a dose-
dependent relaxation to acetylcholine (ACh, 10-8 to 10-3 
M), whereas sodium nitroprusside (SNP, 10-8 to 10-3 M) 
was used as an endothelium-independent agonist. 
Relaxation responses to ACh and SNP were expressed as 
percentage of relaxation from submaximal phenylephrine-
Table 1. Influence of gliclazide on body weight, blood glucose, fasting insulin, lipids and free fatty acids (FFAs) in GKAD rats. 
 
 WISTAR GK GKAD GKAD+G 
Body weight (g) 403.9 ± 6.9 312.7 ± 5.8*** 387.3 ± 4.3§§§ 395.3 ± 5.2§§§ 
FBG (mmol/l) 3.64 ± 0.11 5.17 ± 0.14*** 7.78 ± 0.16*** §§§ 5.45 ± 0.13*** φφφ 
BG 2 h after load (mmol/l) 4.65 ± 0.15 16.62 ± 0.4*** 16.83 ± 0.83*** 17.61 ± 1.57*** 
Insulin (pmol/l) 119.8 ± 30.1 265.9 ± 18.6*** 189.9 ± 19.1* § 105.0 ± 19.2§§§ φ 
Cholesterol (mmol/l) 1.82 ± 0.04 2.3 ± 0.05 2.6 ± 0.14*** §§§ 2.4 ± 0.06*** φ 
Non-HDL cholesterol (mmol/) 0.7 ± 0.04 0.71 ± 0.07 1.29 ± 0.13*** §§§ 1.18 ± 0.05*** φ 
Triglycerides (mmol/l) 1.23 ± 0.09 1.69 ± 0.13* 2.52 ± 0.23*** §§§ 2.24 ± 0.08*** §§ 
FFAs (mmol/l) 0.71 ± 0.08 0.79 ± 0.04 1.13 ± 0.04*** §§ 0.66 ± 0.09φφφ 
 
Values are mean ± S.E.M. * P<0.05, *** P<0.001 vs. Wistar rats; § P<0.05, §§ P<0.01, §§§ P<0.001 vs GK rats; φ P<0.05, 
φφφ P<0.001 vs. GKAD rats. FBG – fasting blood glucose. 
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induced constriction (10-7 M). A cumulative dose-efficacy 
curve was determined. Regression analysis using three data 
points along the linear section of the concentration-
response curve was applied to generate an equation from 
which the EC50 values were determined (Sena et al. 2008). 
 
Statistical analysis 
All data were analyzed by standard computer 
programs (GraphPad Prism PC Software version 3.0, 
ANOVA) and are expressed as mean ± S.E.M. 
Significant differences were evaluated using either the  
t-test or ANOVA. P<0.05 was considered significant. 
Dose response curves were fitted by nonlinear regression 
with simplex algorithm. Relaxation responses were given 
as the percentage of phenylephrine-induced constriction. 
Comparisons of dose-response curves were evaluated by 
2-way ANOVA for repeated measures.  
 
Results 
 
Blood parameters and body weight 
Diabetic GK rats fed a normal chow diet were 
 
 
Fig. 1. Reduction of oxidative 
stress parameters by gliclazide. 
Panels show urinary 8-OHdG (A) 
and plasma protein-bound 
carbonyls (B) levels in Wistar, GK 
control and GK rats fed a high-fat 
diet with (GKAD+G) or without 
gliclazide (GKAD). Results are 
mean ± SEM. *** P<0.001 vs. 
Wistar group; § P<0.05, §§§ P<0.001 
vs. GK group; φ P<0.05 vs. GKAD 
group. 
 
 
 
Fig. 2. Effects of diabetes, high-fat diet and gliclazide treatment on vasodilatory responses to acetylcholine (A) and sodium 
nitroprusside (B) of phenylephrine-precontracted rat thoracic aortic rings. Vasorelaxation was measured using an isometric force 
displacement transducer. Data are expressed as mean ± SEM. *** P<0.001 vs. Wistar group; §§ P<0.01, §§§ P<0.001 vs. GK group; 
φφ P<0.01, φφφ P<0.001 vs. GKAD group.  
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hyperglycemic and hyperinsulinemic compared to Wistar 
rats. GK rats were normolipidemic and their body weight 
was decreased when compared with Wistar rats (Table 1).  
After four months of high-fat diet feeding, GK 
diabetic rats showed a significant increase in body 
weight, fasting glycemia, total and non-HDL-cholesterol, 
triglycerides and FFA levels when compared with GK 
rats receiving a standard diet (Table 1). Treatment of the 
animals with gliclazide in drinking water significantly 
decreased fasting glycemia and insulinemia, total and 
non-HDL-cholesterol and FFA levels. The treatment did 
not modify body weight, triglyceride and glucose levels 
2 h after glucose load (Table 1). Food consumption and 
water intake did not significantly change over the 
experimental period between the different groups studied 
(data not shown). 
 
Oxidative stress biomarkers 
Urinary levels of 8-OHdG were significantly 
higher in GK rats, when compared to age-matched Wistar 
rats (Fig. 1A), while plasma levels of protein carbonyl 
compounds were not statistically different between the 
two groups. Feeding AD diet for 4 months to GK rats 
significantly increased protein carbonyl compounds 
levels by 62 % (Figs 1A and 1B) and did not changed the 
levels of 8-OHdG. Supplementation with gliclazide 
significantly reduced these oxidative stress parameters 
(Figs 1A and 1B). 
ACh- and NO-induced relaxation in rat aortic segments 
The addition of ACh or NO to vessels previously 
contracted with phenylephrine caused a concentration-
dependent relaxation (Figs 2A and 2B). In GK rats 
endothelium-mediated vascular relaxation by ACh of 
aortic rings that were previously contracted with 
phenylephrine was impaired compared with age-matched 
Wistar rats. Indeed, maximal endothelium-mediated 
relaxation of phenylephrine-precontracted rings in 
response to ACh was decreased by 23 % and the EC50 
value of endothelium-independent relaxation to SNP was 
significantly increased (Figs 2A and 2B). The AD diet 
further impaired vascular relaxation in response to both 
ACh and SNP in GK rats. Gliclazide treatment improved 
endothelium-dependent vascular relaxation in GK rats fed 
AD diet. Indeed, when ACh-induced relaxation was 
observed in aortic segments from GKAD+G a significant 
increase in sensitivity to ACh was observed without 
major changes in maximum relaxation (Fig. 2, Table 2, 
P<0.001). Endothelium-denuded rings from all groups 
showed no relaxation to ACh (data not shown). The 
addition of gliclazide (10 μmol/l) in vitro to aorta from 
GKAD rats had no significant effect on relaxation in 
response to acetylcholine (10−9-10−3 mol/l, Fig. 3).  
The EC50 values for ACh- and NO-evoked 
relaxation in aortic segments from Wistar and GK 
diabetic rats are shown in Table 2. The EC50 for ACh in 
the GKAD group was significantly increased (P<0.001 
vs. untreated diabetic rats). The sensitivity of the 
response evoked by ACh or NO in aortic segments from 
GKAD+G was significantly higher than in untreated 
diabetic animals (Table 2, EC50 values significantly 
decreased, P<0.001).  
Preincubation of the arterial rings with the NOS 
inhibitor N -nitro-L-arginine methyl ester (L-NAME) 
and the cyclooxygenase inhibitor indomethacin caused 
residual relaxations of 15 % in response to ACh in GK 
rats and Wistar rats (data not shown). These relaxations 
were not significantly different between the groups 
studied. 
 
Discussion 
 
Several studies have demonstrated impairment 
of endothelium-dependent relaxation associated with 
diabetes (Fortes et al. 1983, Durante et al. 1988). In GK 
diabetic rats, the reduction in endothelium-dependent 
vasodilation has been observed both in experiments with 
isolated aortic rings (Sena et al. 2008), and mesenteric 
 
Fig. 3. Acetylcholine-induced relaxations of phenylephrine-
precontracted rat thoracic aortic rings from diabetic GK rats fed a
high-fat diet (GKAD). In vitro addition of gliclazide (10 µM) to 
rings from GKAD rats had no significant effect. 
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microvessels (Cheng et al. 2001), indicating that diabetic 
endothelial dysfunction affects both conductance and 
resistance vessels. In the present work, the results 
obtained in aortic rings showed impairment in 
endothelium-mediated responses over the 6-month period 
of the evolution of diabetes in the GK rat model. High-fat 
diet significantly impaired endothelial dysfunction and 
this was improved by treatment with gliclazide for 
4 weeks. 
It is widely accepted that increased oxidative 
stress occurs in diabetes (Baynes 1991, Ceriello et al. 
1993), as documented by the presence of peroxidation 
products (Young et al. 1995) or enhanced generation of 
superoxide anions (Chang et al. 1993). Studies from 
several laboratories indicate that antioxidants improve 
NO-mediated endothelium-dependent relaxation in 
vessels from diabetic animals (Diederich et al. 1994, 
Rodríguez-Mañas et al. 1998, Sena et al. 2008). The main 
objective of this work was to analyze whether gliclazide 
ameliorated normal endothelial function in this rodent 
model of type 2 diabetes with dyslipidemia. Gliclazide 
has metabolic effects since this drug stimulates insulin 
secretion, while it also reduces insulin resistance. 
Therefore, our observed effects can be attributed to both 
direct vascular actions of gliclazide and improved insulin 
secretion/function. Oxidative stress and biochemical 
parameters of the diabetic rats were compared. When 
diabetic rats were treated with 10 mg/kg/day gliclazide, a 
reduction of fasting glycemia and lipid profile to control 
diabetic levels was observed, while there were no 
changes in body weight and two-hour postprandial blood 
glucose. Furthermore, FFAs, 8-OHdG and protein 
carbonyl groups were significantly reduced after 
treatment with gliclazide to the same levels as in non-
diabetic Wistar rats.  
It is interesting to note that the addition of 
10 μM gliclazide to isolated vessels from GKAD rats 
caused no effect. This lack of in vitro effect suggests that 
a direct and immediate free radical scavenging effect of 
gliclazide in vivo (Scott et al. 1991) cannot account for 
the improvement in diabetic endothelial cell dysfunction. 
The effect of gliclazide in vivo could be due to either a 
chronic increase of endothelium-derived vasodilators or a 
decrease of vasoconstrictors. In addition, there is a 
reduction in free radical generation or an increase in free 
radical scavenging. In diabetic patients treated with 
gliclazide, plasma reduced thiols were increased, lipid 
peroxides were decreased, and erythrocyte superoxide 
dismutase activity was elevated (Jennings et al. 1992). 
Our results are also consistent with the idea that 
gliclazide improves diabetic endothelial dysfunction by 
an antioxidant mechanism (Jennings et al. 1992, Desfaits 
et al. 1997, O'Brien and Luo 1997). However, we cannot 
rule out that the metabolic effects of gliclazide may also 
contribute to these observations. It is possible that the 
effect of gliclazide was at least partly mediated via 
improved insulin action as evidenced by the observed 
decrease in blood glucose levels and insulin resistance. In 
agreement with our results of improved endothelial 
function, Pagano et al. (1998) reported that treatment 
with gliclazide enhances ACh-induced relaxation in 
isolated aortic segments of alloxan-induced diabetic 
rabbits.  
In addition, the improvement in endothelial 
function has been reported in streptozotocin-induced 
diabetic rats receiving gliclazide (Vallejo et al. 2000a). 
Others have also reported that gliclazide has antioxidant 
properties in vitro, perhaps reversing the endothelial 
dysfunction caused by highly glycosylated 
oxyhemoglobin in human mesenteric microvessels 
Table 2. Effects of diabetes, high-fat and gliclazide treatment on maximal relaxation responses (%) and EC50 values in response to 
acetylcholine and sodium nitroprusside of phenylephrine-precontracted rat thoracic aortic rings. 
 
 Wistar GK GKAD GKAD+G 
Acetylcholine      
EC50 6.88 ± 0.04 6.9 ± 0.09 5.02 ± 0.14*** §§§ 6.69 ± 0.16φφφ 
Maximal relaxation (%) 99.1 ± 0.9 72.9 ± 1.7*** 60.2 ± 2.1*** §§ 55.4 ± 5.4*** §§§ 
Sodium nitroprusside      
EC50 6.47 ± 0.04 6.2 ± 0.04*** 5.6 ± 0.04*** §§§ 6.67 ± 0.03*** §§§ φφφ 
Maximal relaxation (%) 99.3 ± 1.3 99.9 ± 1.3 99.1 ± 1.6 99.5 ± 1.1 
 
Values are mean ± S.E.M. EC50 values are presented as the negative logarithm (-log10 EC50) of concentration of the agonist. 
*** P<0.001 vs. Wistar rats; §§ P<0.01, §§§ P<0.001 vs. GK rats; φφφ P<0.001 vs. GKAD rats. 
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(Vallejo et al. 2000b).  
The major limitation of this study is that 
gliclazide decreased fasting blood glucose thus we cannot 
rule out that gliclazide leads to improvement of oxidative 
stress and endothelial dysfunction due to the 
improvement in fasting glucose levels.  
A main conclusion of the present study is that 
gliclazide ameliorates the endothelial dysfunction present 
in diabetic rats fed a high-fat diet. These beneficial 
effects on the vasculature may be related to the metabolic 
actions of the drug, to the improvements in plasma lipids 
and fasting glycemia and to its antioxidant properties. 
Indeed, this work shows that gliclazide is able to reduce 
fasting hyperglycemia and systemic oxidative stress, thus 
contributing to increased sensitivity to NO-mediated 
vasodilation in diabetic GK rats with dyslipidemia.  
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